These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24242939)

  • 1. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.
    Chan JG; Tyne AS; Pang A; Chan HK; Young PM; Britton WJ; Duke CC; Traini D
    Pharm Res; 2014 May; 31(5):1239-53. PubMed ID: 24242939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
    Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Mol Pharm; 2016 Mar; 13(3):979-89. PubMed ID: 26808409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel inhalable form of rifapentine.
    Chan JG; Duke CC; Ong HX; Chan JC; Tyne AS; Chan HK; Britton WJ; Young PM; Traini D
    J Pharm Sci; 2014 May; 103(5):1411-21. PubMed ID: 24585270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
    Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D
    Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
    Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
    Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder.
    Chan JG; Tyne AS; Pang A; McLachlan AJ; Perera V; Chan JC; Britton WJ; Chan HK; Duke CC; Young PM; Traini D
    Int J Antimicrob Agents; 2015 Mar; 45(3):319-23. PubMed ID: 25554469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
    Eedara BB; Tucker IG; Das SC
    Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
    Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation.
    Parumasivam T; Ashhurst AS; Nagalingam G; Britton WJ; Chan HK
    Mol Pharm; 2017 Jan; 14(1):328-335. PubMed ID: 27977216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.
    Mangal S; Huang J; Shetty N; Park H; Lin YW; Yu HH; Zemlyanov D; Velkov T; Li J; Zhou QT
    Int J Pharm; 2019 Apr; 561():102-113. PubMed ID: 30797863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J; Kutter JP; Mu H; Moodley A; Yang M
    Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis.
    Eedara BB; Rangnekar B; Sinha S; Doyle C; Cavallaro A; Das SC
    Eur J Pharm Sci; 2018 Jun; 118():216-226. PubMed ID: 29625212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.